Desoxyribonuclease mutant and application thereof in preparation of PDRN
By developing high-energy DNA enzyme mutants in specific amino acid mutations in the DNASE1 gene in bovine pancreatic tissue, PDRN was prepared by single-step enzymatic method, which solved the problems of high-temperature Maillard reaction and cumbersome steps in the existing technology, and improved the Extraction rate and product quality, suitable for industrial production.
Patent Information
- Application Number
- CN202411098540.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-12
AI Technical Summary
The existing PDRN preparation methods have problems such as high temperatures that cause Maillard reaction, complicated steps, long cycles and easy breeding of bacteria, which affect product quality and industrial production efficiency.
A DNA mutant was developed to prepare PDRN by iteratively saturating the specific amino acids of the DNASE1 gene in bovine pancreatic tissue to improve the activity of the enzyme, and combined with appropriate pH and temperature conditions, a single-step enzymatic method was used to prepare PDRN.
It significantly improves the enzyme activity and PDRN extraction rate, avoids Maillard reaction and microbial contamination, simplifies production steps, and improves product quality and industrial applicability.
Smart Images

Figure CN118931877A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a deoxyribonuclease mutant and application thereof in preparing PDRN, belonging to the field of biotechnology. Background Art
[0002] Polydeoxyribonudeotide (PDRN) is a salmon fragment of a specific specification extracted from salmon germ cells. It is generally composed of 50-2000 base pairs. It binds to adenosine A2A receptors, activates multiple signaling pathways, increases anti-inflammatory factors, and produces anti-inflammatory effects. It can also provide purine or pyrimidine through salvage pathways to accelerate DNA synthesis and repair damaged skin cells. Activation of receptors causes osteoblasts, fibroblasts, and fat precursor cells to proliferate, activating damaged cells in the elderly and making them younger. In addition, VEGF, angiogenin, and glutamine transaminase are also released with receptor activation, improving blood circulation and accelerating cell regeneration. In the field of medical beauty injections, PDRN has broad application prospects and huge demand.
[0003] When using salmon testis tissue to extract PDRN, it is first necessary to degrade the high molecular weight genomic DNA to obtain PDRN with an appropriate molecular weight distribution. Common DNA degradation methods include acid degradation, alkaline degradation, enzyme degradation, DNA fragmentation instrument degradation, etc.
[0004] Chinese patent document CN110747194A discloses a method for preparing PDRN, which requires lysing testicular tissue at 90-100°C. Using a DNA fragmentor to break DNA is prone to heat generation and Maillard reaction, which makes the product yellow and affects product quality. It is also difficult to operate in large-scale industrial production.
[0005] Chinese patent document CN112315836A discloses a method for preparing PDRN, which requires pretreatment, cell collection, trypsin hydrolysis, protein removal, alcohol precipitation and restriction endonuclease Sau3 AI hydrolysis to obtain a PDRN product. The method uses mild enzymatic conditions, but the method uses two-step enzymatic hydrolysis, and the enzymatic hydrolysis time is 16 to 48 hours and 5 to 16 hours respectively. It has many steps and a long cycle, and it is easy to breed bacteria and affect the product quality. In addition, the cell collection process requires repeated washing with a mixed salt solution, and the steps are cumbersome and industrially uneconomical.
[0006] The bio-enzymatic method for degrading milt DNA is milder than acid degradation and alkaline degradation, will not damage the molecular structure of DNA, and has stable product quality. However, there is currently a lack of efficient, stable, cost-controlled enzymes suitable for industrial production, which to a certain extent limits the development of enzymatic preparation of PDRN.
[0007] Therefore, developing a deoxyribonuclease mutant and improving the enzymatic efficiency of nuclease on PDRN are of great value for the preparation and extraction of PDRN. Summary of the invention
[0008] In view of the deficiencies in the prior art, the present invention provides a deoxyribonuclease mutant and its application in the preparation of PDRN.
[0009] The technical solution of the present invention is as follows:
[0010] A mutant of deoxyribonuclease, the amino acid sequence of which is shown in SEQ ID NO.1, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.2.
[0011] The deoxyribonuclease mutant provided by the invention is prepared by mutating the alanine (Ala) at position 69 to histidine (His), the serine (Ser) at position 132 to arginine (Arg), and the glutamine (Gln) at position 215 to cysteine (Cys) on the basis of the deoxyribonuclease expressed by the DNASE1 gene from the pancreatic tissue of cattle (Bos taurus) (NCBI accession number is BC142349.1).
[0012] A recombinant vector is a plasmid vector into which the coding gene of the deoxyribonuclease mutant is inserted.
[0013] Preferably according to the present invention, the plasmid vector is pET-28a plasmid.
[0014] A recombinant strain is obtained by transforming the above recombinant vector into a host strain.
[0015] Preferably according to the present invention, the host strain is Escherichia coli.
[0016] The use of the above-mentioned deoxyribonuclease mutant and / or the encoding gene of the deoxyribonuclease mutant in the preparation of PDRN.
[0017] Preferably, according to the present invention, the specific steps of the application are as follows:
[0018] (1) thawing salmon milt in a water bath at 20-30° C., rinsing with purified water, and then crushing with a crusher to obtain a paste-like milt;
[0019] (2) adding purified water to the milt paste of step (1) at 35 to 60° C., stirring evenly, adjusting the pH to 7.0 to 8.5, adding a deoxyribonuclease mutant, and performing enzymatic hydrolysis for 18 to 90 minutes; after the enzymatic hydrolysis, continuing to add urea and sodium sulfate at 35 to 60° C., stirring and incubating for 0.5 to 1.5 hours, to obtain an enzymatic hydrolyzate; and obtaining PDRN after alcohol precipitation, washing, and drying.
[0020] Further preferably, in step (2), the mass ratio of the paste-like milt to purified water is 1:10, g / mL; the mass ratio of the paste-like milt to the deoxyribonuclease mutant is 1:(0.01-0.08); the mass ratio of the paste-like milt to urea is 1:(0.03-0.07); the mass ratio of the paste-like milt to sodium sulfate is 1:(0.2-0.6).
[0021] The beneficial effects of the present invention are:
[0022] 1. The present invention is based on the deoxyribonuclease expressed by the DNASE1 gene of the pancreatic tissue of cattle (Bos taurus) (NCBI accession number is BC142349.1), and selects the amino acids at positions 69, 132 and 215 for iterative saturation mutation, mutating the alanine (Ala) at position 69 to histidine (His), the serine (Ser) at position 132 to arginine (Arg), and the glutamine (Gln) at position 215 to cysteine (Cys). Compared with the wild-type deoxyribonuclease (NCBI accession number is BC142349.1), the enzyme activity of the deoxyribonuclease mutant A69H-S132R-Q215C provided by the present invention is increased by 2.15 times, reaching 4.1×10 6 U / mL.
[0023] 2. The deoxyribonuclease mutant A69H-S132R-Q215C provided by the present invention can be used to prepare and extract PDRN, with an extraction rate of 15.2%, a DNA content of 99.1%, and a molecular weight of PDRN of 1.05 million Daltons, which is significantly improved compared to the wild-type enzyme; at the same time, it can also avoid the Maillard reaction that is prone to occur at high temperatures, and overcome the problems of cumbersome two-step enzymatic hydrolysis steps, long production cycle, and easy microbial contamination. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The 3D structural model of the deoxyribonuclease mutant A69H-S132R-Q215C.
[0025] Figure 2 It is the nucleic acid electrophoresis diagram of the deoxyribonuclease mutant A69H-S132R-Q215C and the wild-type enzyme;
[0026] In the figure, lane 1 is the DNAse mutant A69H-S132R-Q215C, and lane 2 is the wild-type enzyme.
[0027] Figure 3 The electrophoretograms of PDRN extracted from Comparative Example 1 and Example 4 are shown;
[0028] In the figure, lane 1 is comparative example 1, and lane 2 is example 4. DETAILED DESCRIPTION
[0029] The following examples of the present invention only illustrate specific implementation schemes for implementing the present invention. These schemes should not be understood as limiting the present invention. Any changes made without departing from the principle and essence of the present invention fall within the protection scope of the present invention.
[0030] The experimental techniques and methods used in this example are all conventional technical methods unless otherwise specified. The materials, reagents, etc. used in this example can be obtained through regular commercial channels unless otherwise specified.
[0031] The Escherichia coli used in the present invention is a common commercially available strain, which can be purchased from a microbial collection center or a strain sales company.
[0032] Example 1: Selection of mutation sites
[0033] Based on the amino acid sequence of the deoxyribonuclease expressed by the DNASE1 gene of the pancreatic tissue of cattle (Bos taurus) (NCBI accession number BC142349.1), homology modeling (100% identity) was performed on SWISS-MODEL to generate a PDB file. The 3D model is shown in Figure 1 According to the conserved region 66 / 134 / 212 of DNASE1 gene expressed by bovine (Bos taurus) pancreatic tissue (NCBI accession number BC142349.1), combined with sequence conservation analysis and 3D model analysis, A69, S132 and Q215 of DNASE1 were selected as potential mutation sites.
[0034] Example 2. Obtaining mutant genes
[0035] 1. Entrust BGI to artificially synthesize the nucleotide sequence of DNASE1 gene according to the information of NCBI accession number BC142349.1, and then use restriction enzymes Nhe I and Xho I to connect the DNASE1 gene to the plasmid vector pET-28a to obtain the recombinant plasmid pET-28a-DNASE1; then introduce the recombinant plasmid pET-28a-DNASE1 into Escherichia coli BL21 competent cells by heat shock method to obtain the engineered bacteria BL21-pET-28a-DNASE1 containing wild-type deoxyribonuclease, and store it at -80℃.
[0036] 2. Through three rounds of iterative saturation mutation and superior strain screening, the DNASE1 mutant gene was obtained. The specific method is as follows:
[0037] Round 1: Using the recombinant plasmid pET-28a-DNASE1 as a template and F69 and R69 as primers, the alanine at position 69 of its amino acid sequence was mutated to the remaining 19 amino acids by site-directed saturation mutagenesis PCR, and then transformed into Escherichia coli, coated with LB solid medium and cultured, and the strain BL21-pET-28a-DNASE1-A69H was obtained through screening of dominant strains;
[0038] Screening method for dominant strains: select mutant single colonies from LB solid culture medium, inoculate into 96-well plates containing 500 μL of LB liquid culture medium, and culture at 37°C, 220 rpm for 15 h. Inoculate into 96-well plates containing 500 μL of LB liquid culture medium at a 2% (v / v) inoculation amount, and culture at 37°C, 220 rpm for 3 h. After adding IPTG with a final concentration of 0.1 mmol / L, induce culture at 20°C for 15 h. Detect enzyme activity respectively.
[0039] Enzyme activity detection conditions: 40 mM Tris-HCl (pH 8.0), 10 mM MgSO4, 1 mM CaCl2, 1 μg pBR322 plasmid DNA.
[0040] Enzyme activity definition: 1 unit of activity is the amount of enzyme required to completely degrade 1 μg of pBR322 plasmid DNA at 37°C within 10 minutes.
[0041] Round 2: Using the recombinant plasmid extracted from the strain BL21-pET-28a-DNASE1-A69H as a template and F132 and R132 as primers, the serine at position 132 of its amino acid sequence was mutated to the remaining 19 amino acids by site-directed saturation mutagenesis PCR, and then transformed into Escherichia coli, coated with LB solid medium and cultured, and the dominant strain was screened according to the method described in the first round to obtain the strain BL21-pET-28a-DNASE1-A69H-S132R.
[0042] Round 3: Using the recombinant plasmid extracted from the strain BL21-pET-28a-DNASE1-A69H-S132R as a template and F215 and R215 as primers, the glutamine at position 215 of its amino acid sequence was mutated to the remaining 19 amino acids by saturation mutation PCR, and then transformed into Escherichia coli, coated with LB solid medium and cultured, and the dominant strain was screened according to the method described in the first round to obtain the strain BL21-pET-28a-DNASE1-A69H-S132R-Q215C.
[0043] The mutation system (25 μL) is shown in the following table.
[0044]
[0045]
[0046] PCR conditions: pre-denaturation at 95°C for 5 min, 30 cycles at 90°C for 30 s, 62°C for 30 s, 72°C for 7 min, and final extension at 72°C for 5 min.
[0047] The recombinant plasmid was extracted from the strain BL21-pET-28a-DNASE1-A69H-S132R-Q215C, and then the DNA agarose gel electrophoresis was performed to verify the positive result. Figure 2 As shown. Figure 2 It can be seen that the target band appears in the gel electrophoresis diagram and the band is single, indicating that the deoxyribonuclease gene mutation is successful and the expression is successful.
[0048] The specific mutation upstream primers and downstream primers are shown in Table 1.
[0049] Table 1
[0050] Primer name Primer sequence (5'-3') F69 agccacctggtgnnkgtggggaagc R69 ttccccacknncaccaggtggctg F132 aacgacagcttcnnkcgggagcc R132 ggctcccgknngaagctgtcgttc F215 agctccaccttcnnktggctgattc R215 aatcagccaknngaaggtggagctcg
[0051] Example 3: Screening of enzyme mutants
[0052] 1. Preparation of enzyme mutants: Taking the deoxyribonuclease mutant A69H-S132R-Q215C as an example, the strain BL21-pET-28a-DNASE1-A69H-S132R-Q215C was inoculated into an LB liquid medium containing a final concentration of 50 mg / L kanamycin, cultured for 12 hours, and then inoculated into a fresh LB liquid medium containing a final concentration of 50 mg / L kanamycin at an inoculum size of 2% (v / v), cultured for 4 hours, added with IPTG at a final concentration of 0.1 mmol / L, and then induced at 20°C for 12 hours to obtain a fermentation broth; the fermentation broth was centrifuged to obtain wet cells, the wet cells were added with phosphate buffer and ultrasonically disrupted, and then centrifuged to obtain a supernatant, which was the deoxyribonuclease mutant A69H-S132R-Q215C.
[0053] Wild-type deoxyribonuclease DNASE1, deoxyribonuclease mutant A69H, deoxyribonuclease mutant A69R, deoxyribonuclease mutant A69Q, deoxyribonuclease mutant A69H-S132K, deoxyribonuclease mutant A69H-S132R, deoxyribonuclease mutant A69H-S132W, deoxyribonuclease mutant A69H-S132R-Q215A, deoxyribonuclease mutant A69H-S132R-Q215M and deoxyribonuclease mutant A69H-S132R-Q215Y were prepared according to the same method.
[0054] 2. The enzyme activities of wild-type deoxyribonuclease DNASE1, deoxyribonuclease mutant A69H, deoxyribonuclease mutant A69R, deoxyribonuclease mutant A69Q, deoxyribonuclease mutant A69H-S132K, deoxyribonuclease mutant A69H-S132R, deoxyribonuclease mutant A69H-S132W, deoxyribonuclease mutant A69H-S132R-Q215A, deoxyribonuclease mutant A69H-S132R-Q215C, deoxyribonuclease mutant A69H-S132R-Q215M and deoxyribonuclease mutant A69H-S132R-Q215Y were determined according to the method described in Example 2. The results are shown in Table 2.
[0055] Table 2
[0056] Strain number Enzyme activity (U / mL) Enzyme activity increase rate (%) BL21-pET-28a-DNASE1 <![CDATA[1.3×10 6 ]]> - BL21-pET-28a-DNASE1-A69H <![CDATA[2.0×10 6 ]]> 53.8 BL21-pET-28a-DNASE1-A69R <![CDATA[1.6×10 6 ]]> 23.1 BL21-pET-28a-DNASE1-A69Q <![CDATA[1.4×10 6 ]]> 7.7 BL21-pET-28a-DNASE1-A69H-S132K <![CDATA[2.1×10 6 ]]> 61.5 BL21-pET-28a-DNASE1-A69H-S132R <![CDATA[2.7×10 6 ]]> 107.7 BL21-pET-28a-DNASE1-A69H-S132W <![CDATA[2.1×10 6 ]]> 61.5 BL21-pET-28a-DNASE1-A69H-S132R-Q215A <![CDATA[2.9×10 6 ]]> 123.1 BL21-pET-28a-DNASE1-A69H-S132R-Q215C <![CDATA[4.1×10 6 ]]> 215.4 BL21-pET-28a-DNASE1-A69H-S132R-Q215M <![CDATA[2.6×10 6 ]]> 100 BL21-pET-28a-DNASE1-A69H-S132R-Q215Y <![CDATA[3.8×10 6 ]]> 192.3
[0057] As shown in Table 2, the enzyme activity of the DNA enzyme mutants was higher than that of the wild-type DNA enzyme, and the enzyme activity of the DNA enzyme mutant A69H-S132R-Q215C reached 4.1×10 6 U / mL, the enzyme activity of the wild-type deoxyribonuclease was increased by 2.15 times.
[0058] Example 4: Preparation of PDRN using the deoxyribonuclease mutant A69H-S132R-Q215C
[0059] A method for preparing PDRN using a deoxyribonuclease mutant A69H-S132R-Q215C comprises the following steps:
[0060] (1) taking out the frozen salmon milt, thawing it in a water bath at 25° C., rinsing it with purified water, and then crushing it using a crusher to obtain a paste-like milt;
[0061] (2) At 50°C, 1000 mL of purified water was added to 100 g of the milt paste prepared in step (1) and the mixture was stirred evenly. The pH was adjusted to 8.0 using 1 mol / L sodium hydroxide solution and 0.3 g of the mutant deoxyribonuclease was added.
[0062] A69H-S132R-Q215C, 50℃ enzymatic hydrolysis for 60min; after enzymatic hydrolysis, continue to add 8g of urea and 40g of sodium sulfate, stir and incubate for 1h to obtain enzymatic hydrolyzate; add 95% ethanol to the enzymatic hydrolyzate until the ethanol concentration in the mixture is more than 50%, so that PDRN precipitates, let stand and layer, discard the supernatant and retain the precipitate, add 75% ethanol with a volume of 3 times the precipitate, stir and wash, let stand and layer, discard the supernatant and retain the precipitate, add 85% ethanol with a volume of 3 times the precipitate, stir and wash, let stand and layer, discard the supernatant and retain the precipitate, add 95% ethanol with a volume of 4 times the precipitate, dehydrate for more than 2h, put it in a vacuum oven, and dry it at 45℃ for 4h to obtain PDRN;
[0063] The PDRN prepared in this example has the appearance of white granules or powder, with a yield of 15.2%, a content of 99.1%, a protein content of 0.5%, an endotoxin of 0.4 EU / mg, and a molecular weight of 1.05 million Daltons ( Figure 3 middle lane 2).
[0064] Comparative Example 1
[0065] The paste-like milt was prepared by using wild-type deoxyribonuclease DNASE1 according to the method (1) described in Example 4. The specific method is as follows:
[0066] At 50°C, 1000mL of purified water was added to 100g of paste-like milt and stirred evenly, 0.3g of wild-type deoxyribonuclease DNASE1 was added after adjusting the pH to 8.0 with 1mol / L sodium hydroxide solution, and the mixture was enzymolyzed at 50°C for 60min; after enzymolysis, 8g of urea and 40g of sodium sulfate were added, and the mixture was stirred and incubated for 1h to obtain an enzymolysis solution; 95% ethanol was added to the enzymolysis solution until the ethanol concentration in the mixture was more than 50%, so that PDRN was precipitated, 75% ethanol was discarded and retained by standing and stratification, 3 times the volume of the precipitate was added, and the precipitate was stirred and washed, the supernatant was discarded and retained by standing and stratification, 3 times the volume of the precipitate was added, 85% ethanol was stirred and washed, the supernatant was discarded and retained by standing and stratification, 4 times the volume of the precipitate was added, and the precipitate was dehydrated for more than 2h, and the mixture was placed in a vacuum oven and dried at 45°C for 4h to obtain PDRN;
[0067] The PDRN prepared in this comparative example has a yellow flake or filamentous solid appearance, a yield of 10.9%, a content of 92.3%, a protein content of 0.8%, an endotoxin of 0.9EU / mg, and a molecular weight of 4.2 million Daltons ( Figure 3 middle lane 1).
[0068] Through data comparison, it can be seen that Example 4 of the present invention uses the deoxyribonuclease mutant A69H-S132R-Q215C to prepare a method for extracting PDRN, and the extraction rate and DNA content are higher than those of Comparative Example 1, and the molecular weight of the prepared PDRN is also less than that of Comparative Example 1, which is significantly improved compared to the wild-type enzyme in all aspects; at the same time, it can also avoid the Maillard reaction that is prone to occur at high temperatures, and overcome the problems of cumbersome two-step enzymatic hydrolysis steps, long production cycle and prone to microbial contamination.
Claims
1. A deoxyribonuclease mutant, It is characterized in that The amino acid sequence is shown in SEQ ID NO.1, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.
2.
2. A recombinant vector, It is characterized in that The gene encoding the deoxyribonuclease mutant according to claim 1 is inserted into a plasmid vector.
3. The recombinant vector according to claim 2, It is characterized in that The plasmid vector is pET-28a plasmid.
4. A recombinant strain, It is characterized in that The recombinant vector of claim 2 is transformed into a host strain.
5. The recombinant vector according to claim 4, It is characterized in that The host strain is Escherichia coli.
6. Application of the deoxyribonuclease mutant according to claim 1 in the preparation of PDRN.
7. The use according to claim 6, It is characterized in that The specific steps of the application are as follows: (1) thawing salmon milt in a water bath at 20-30° C., rinsing with purified water, and then crushing with a crusher to obtain a paste-like milt; (2) adding purified water to the milt paste of step (1) at 35 to 60° C., stirring evenly, adjusting the pH to 7.0 to 8.5, adding the mutant deoxyribonuclease according to claim 1, and performing enzymatic hydrolysis for 18 to 90 min; after the enzymatic hydrolysis, continuing to add urea and sodium sulfate at 35 to 60° C., stirring and incubating for 0.5 to 1.5 h, to obtain an enzymatic hydrolyzate; and obtaining PDRN after alcohol precipitation, washing and drying.
8. The use according to claim 7, It is characterized in that In step (2), the mass ratio of the paste-like milt to purified water is 1:10, g / mL; the mass ratio of the paste-like milt to the deoxyribonuclease mutant is 1:(0.01-0.08); the mass ratio of the paste-like milt to urea is 1:(0.03-0.07); the mass ratio of the paste-like milt to sodium sulfate is 1:(0.2-0.6).
Citation Information
Patent Citations
Small molecule polydeoxyribonucleotide and preparation and application thereof
CN110747194A
Preparation method and application of efficient external PDRN
CN112315836A
Heat-labile desoxyribonuclease i variants
CA2453872A1
Paraoxonase fusion polypeptides and related compositions and methods
CA3206901A1
Secretory expression method of DNaseI
CN115975979A
